Effect of oral immunization with pooled antigens derived from adipose tissue on atherosclerosis and obesity indices

Vaccine

Volumn 28, Issue 15, 2010, Pages 2763-2768

  Bourinbaiar, Aldar S ^a   Jirathitikal, Vichai ^b  

^a Immunitor USA Inc   (United States)

^b Bangpakong Industrial Park   (Thailand)

Author keywords

Adipocyte; Atherogenesis; Atherosclerosis; Cholesterol; Diabetes; HDL; Immune tolerance; Immunotherapy; LDL; Obesity; Overweight; Therapeutic vaccine; Triglycerides

Indexed keywords

ADIPOSE TISSUE ANTIGEN; ALANINE AMINOTRANSFERASE; ANTIGEN; ASPARTATE AMINOTRANSFERASE; CHOLESTEROL; CREATININE; GLUCOSE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; NITROGEN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UREA; V 6;

ACTIVE IMMUNIZATION; ADIPOSE TISSUE; ARM CIRCUMFERENCE; ARTICLE; ATHEROSCLEROSIS; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG SAFETY; EOSINOPHIL COUNT; ERYTHROCYTE COUNT; ERYTHROCYTE VOLUME; FEMALE; GLUCOSE BLOOD LEVEL; HEMATOCRIT; HUMAN; HUMAN EXPERIMENT; LEUKOCYTE COUNT; MALE; NEUTROPHIL COUNT; NORMAL HUMAN; OBESITY; PRIORITY JOURNAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TABLET FORMULATION; THIGH; THROMBOCYTE COUNT; UREA NITROGEN BLOOD LEVEL; WAIST CIRCUMFERENCE;

ADIPOSE TISSUE; ADMINISTRATION, ORAL; ADULT; AGED; ANIMALS; ANTIGENS; ATHEROSCLEROSIS; BLOOD PHYSIOLOGICAL PHENOMENA; BLOOD PRESSURE; CHOLESTEROL; FEMALE; HUMAN EXPERIMENTATION; HUMANS; IMMUNIZATION; KIDNEY; LIPOPROTEINS, HDL; LIPOPROTEINS, LDL; LIVER; MALE; MIDDLE AGED; OBESITY; TRIGLYCERIDES; VACCINES; YOUNG ADULT;

EID: 77949269462     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.01.032     Document Type: Article

References (58)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3421
2. Bamba V., and Rader D.J. Obesity and atherogenic dyslipidemia. Gastroenterology 132 (2007) 2181-2190
3. Padwal R., Li S.K., and Lau D.C. Long-term pharmacotherapy for obesity and overweight. Cochrane Database Syst Rev 4 (2003) CD004094
4. Mayerl C., Lukasser M., Sedivy R., Niederegger H., Seiler R., and Wick G. Atherosclerosis research from past to present-on the track of two pathologists with opposing views, Carl von Rokitansky and Rudolf Virchow. Virchows Arch 449 (2006) 96-103
5. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 444 (2006) 860-867
6. Hansson G.K., and Nilsson J. Vaccination against atherosclerosis? Induction of atheroprotective immunity. Semin Immunopathol 31 (2009) 95-101
7. Zorrilla E.P., Iwasaki S., Moss J.A., Chang J., Otsuji J., Inoue K., et al. Vaccination against weight gain. Proc Natl Acad Sci USA 103 (2006) 13226-13231
8. Fulurija A., Lutz T.A., Sladko K., Osto M., Wielinga P.Y., Bachmann M.F., et al. Vaccination against GIP for the treatment of obesity. PLoS One 3 (2008) e3163
9. Gero S., Gergely J., Jakab L., Virag S., Farkas K., and Czuppon A. Inhibition of cholesterol atherosclerosis by immunisation with beta-lipoprotein. Lancet 2 (1959) 6-7
10. Zubzhitskii Yu.N., Nagornev V.A., Lovyagina T.N., and Ban'kovskaya E.B. Prevention of experimental atherosclerosis by parenteral injection of atherogenic lipoproteins into newborn rabbits. Bull Exp Biol Med 71 (1971) 113-114
11. Klimov A.N., Loviagina T.N., Nagornev V.A., Zubzhitskiǐ IuN, and Petrova-Maslakova L.G. Nature of the lipoprotein antigen responsible for the development of resistance to experimental atherosclerosis following its use in immunization of newborn rabbits. Vopr Med Khim 24 (1978) 131-136
12. Bailey J.M., Bright R., and Tomar R. Immunization with a synthetic cholesterol-ester antigen and induced atherosclerosis in rabbits. Nature 201 (1964) 407-408
13. Arnold A., McAuliff J.P., Lewis L.J., and Coulston F. Atherosclerosis in rabbits following treatment with heterologous lipoprotein. J Atheroscler Res 1 (1961) 240-246
14. Siegler P.E., Ro S.J., Nodine J.H., Faludi-Siegler G., Spitzer J.A., and Spitzer J.J. Effect of immunisation with β-lipoprotein on cholesterol atherosclerosis. Lancet 277 (1961) 403
15. Davidson M.H., Maki K., Umporowicz D., Wheeler A., Rittershaus C., and Ryan U. The safety and immunogenicity of a CETP vaccine in healthy adults. Atherosclerosis 169 (2003) 113-120
16. Silin D.S., Lyubomska O.V., Jirathitikal V., and Bourinbaiar A.S. Oral vaccination: where we are?. Expert Opin Drug Deliv 4 (2007) 323-340
17. Kantachuvessiri A. Obesity in Thailand. J Med Assoc Thai 88 April (4) (2005) 554-562
18. Berg A.H., and Scherer P.E. Adipose tissue, inflammation, and cardiovascular disease. Circ Res 96 (2005) 939-949
19. Reinis Z., Lojda Z., Heyrovský A., Horáková D., and John C. Effect of immunization on experimental atherosclerosis in poultry. Sb Lek 78 (1976) 64-70
20. Zubzhitskiǐ IuN, and Alksnis E.G. Effect of immunization with small doses of antigen on the development of experimental atherosclerosis. Biull Eksp Biol Med 90 (1980) 286-288
21. Xu Q., Dietrich H., Steiner H.J., Gown A.M., Schoel B., Mikuz G., et al. Induction of arteriosclerosis in normocholesterolemic rabbits by immunization with heat shock protein 65. Arterioscl Thromb 12 (1992) 789-799
22. Bailey J.M., Bright R., Tomar R., and Butler J. Anti-atherogenic effects of cholesterol vaccination. Biochem Soc Trans 22 (1994) 433S
23. Palinski W., Miller E., and Witztum J. Immunization of low density lipoprotein (LDL) receptor deficient rabbits with homologous malondialdehyde-modified LDL reduces atherosclerosis. Proc Natl Acad Sci USA 92 (1995) 821-825
24. Alving C.R., Swartz Jr. G.M., Wassef N.M., Ribas J.L., Herderick E.E., Virmani R., et al. Immunization with cholesterol-rich liposomes induces anti-cholesterol antibodies and reduces diet-induced hypercholesterolemia and plaque formation. J Lab Clin Med 127 (1996) 40-49
25. Ameli S., Hultgårdh-Nilsson A., Regnström J., Calara F., Yano J., Cercek B., et al. Effect of immunization with homologous LDL and oxidized LDL on early atherosclerosis in hypercholesterolemic rabbits. Arterioscler Thromb Vasc Biol 16 (1996) 1074-1079
26. Xu Q., Kleindienst R., Schett G., Waitz W., Jindal S., Gupta R.S., et al. Regression of arteriosclerotic lesions induced by immunization with heat shock protein 65-containing material in normocholesterolemic, but not hypercholesterolemic, rabbits. Atherosclerosis 123 (1996) 145-155
27. Fabricant C.G., and Fabricant J. Atherosclerosis induced by infection with Marek's disease herpesvirus in chickens. Am Heart J 138 (1999) S465-S468
28. George J., Afek A., Gilburd B., Blank M., Levy Y., Aron-Maor A., et al. Induction of early atherosclerosis in LDL-receptor-deficient mice immunized with beta2-glycoprotein I. Circulation 98 (1998) 1108-1115
29. George J., Afek A., Gilburd B., Levkovitz H., Shaish A., Goldberg I., et al. Hyperimmunization of apo-E-deficient mice with homologous malondialdehyde low-density lipoprotein suppresses early atherogenesis. Atherosclerosis 138 (1998) 147-152
30. Metzler B., Mayr M., Dietrich H., Singh M., Wiebe E., Xu Q., et al. Inhibition of arteriosclerosis by T-cell depletion in normocholesterolemic rabbits immunized with heat shock protein 65. Arterioscler Thromb Vasc Biol 19 (1999) 1905-1911
31. Afek A., George J., Gilburd B., Rauova L., Goldberg I., Kopolovic J., et al. Immunization of low-density lipoprotein receptor deficient (LDL-RD) mice with heat shock protein 65 (HSP-65) promotes early atherosclerosis. J Autoimmun 14 (2000) 115-121
32. Zhou X., Caligiuri G., Hamsten A., Lefvert A.K., and Hansson G.K. LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis. Arterioscler Thromb Vasc Biol 21 (2001) 108-114
33. Tsimikas S., Palinski W., and Witztum J.L. Circulating autoantibodies to oxidized LDL correlate with arterial accumulation and depletion of oxidized LDL in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 21 (2001) 95-100
34. Maron R., Sukhova G., Faria A.M., Hoffmann E., Mach F., Libby P., et al. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation 106 (2002) 1708-1715
35. van Puijvelde G.H., Hauer A.D., de Vos P., van den Heuvel R., van Herwijnen M.J., van der Zee R., et al. Induction of oral tolerance to oxidized low-density lipoprotein ameliorates atherosclerosis. Circulation 114 (2006) 1968-1976
36. Asgary S., Saberi S.A., and Azampanah S. Effect of immunization against ox-LDL with two different antigens on formation and development of atherosclerosis. Lipids Health Dis 6 (2007) 32
37. Rittershaus C.W., Miller D.P., Thomas L.J., Picard M.D., Honan C.M., Emmett C.D., et al. Vaccine-induced antibodies inhibit CETP activity in vivo and reduce aortic lesions in a rabbit model of atherosclerosis. Arterioscler Thromb Vasc Biol 20 (2000) 2106-2112
38. Hauer A.D., Uyttenhove C., de Vos P., Stroobant V., Renauld J.C., van Berkel T.J., et al. Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation 112 (2005) 1054-1062
39. Habets K.L., van Puijvelde G.H., van Duivenvoorde L.M., van Wanrooij E.J., de Vos P., Tervaert J.W., et al. Vaccination using oxLDL-pulsed dendritic cells reduces atherosclerosis in LDL receptor-deficient mice. Cardiovasc Res October (2009) [Epub ahead of print]
40. Hansen P.R., Chew M., Zhou J., Daugherty A., Heegaard N., Jensen P., et al. Freunds adjuvant alone is antiatherogenic in apoE-deficient mice and specific immunization against TNFalpha confers no additional benefit. Atherosclerosis 158 (2001) 87-94
41. Gaofu Q., Jun L., Xin Y., Wentao L., Jie W., Xiuyun Z., et al. Vaccinating rabbits with a cholesteryl ester transfer protein (CETP) B-Cell epitope carried by heat shock protein-65 (HSP65) for inducing anti-CETP antibodies and reducing aortic lesions in vivo. J Cardiovasc Pharmacol 45 (2005) 591-598
42. Yuan X., Yang X., Cai D., Mao D., Wu J., Zong L., et al. Intranasal immunization with chitosan/pCETP nanoparticles inhibits atherosclerosis in a rabbit model of atherosclerosis. Vaccine 26 (2008) 3727-3734
43. George J., Yacov N., Breitbart E., Bangio L., Shaish A., Gilburd B., et al. Suppression of early atherosclerosis in LDL-receptor deficient mice by oral tolerance with beta 2-glycoprotein I. Cardiovasc Res 62 (2004) 603-609
44. Petrovan R.J., Kaplan C.D., Reisfeld R.A., and Curtiss L.K. DNA vaccination against VEGF receptor 2 reduces atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 27 (2007) 1095-1100
45. Hauer A.D., van Puijvelde G.H., Peterse N., de Vos P., van Weel V., van Wanrooij E.J., et al. Vaccination against VEGFR2 attenuates initiation and progression of atherosclerosis. Arterioscler Thromb Vasc Biol 27 (2007) 2050-2057
46. van Wanrooij E.J., de Vos P., Bixel M.G., Vestweber D., van Berkel T.J., and Kuiper J. Vaccination against CD99 inhibits atherogenesis in low-density lipoprotein receptor-deficient mice. Cardiovasc Res 78 (2008) 590-596
47. Hauer A.D., Habets K.L., van Wanrooij E.J., de Vos P., Krueger J., Reisfeld R.A., et al. Vaccination against TIE2 reduces atherosclerosis. Atherosclerosis 204 (2009) 365-371
48. Caligiuri G., Khallou-Laschet J., Vandaele M., Gaston A.T., Delignat S., Mandet C., et al. Phosphorylcholine-targeting immunization reduces atherosclerosis. J Am Coll Cardiol 50 (2007) 540-546
49. Binder C.J., Hörkkö S., Dewan A., Chang M.K., Kieu E.P., Goodyear C.S., et al. Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med 9 (2003) 736-743
50. Goldenberg I., Benderly M., Sidi R., Boyko V., Tenenbaum A., Tanne D., et al. Relation of clinical benefit of raising high-density lipoprotein cholesterol to serum levels of low-density lipoprotein cholesterol in patients with coronary heart disease (from the Bezafibrate Infarction Prevention Trial). Am J Cardiol 103 (2009) 41-45
51. Boden W.E. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am J Cardiol 86 (2000) 19L-22L
52. Ostfeld R., Mookherjee D., Spinelli M., Holtzman D., Shoyeb A., Schaefer M., et al. A triglyceride/high-density lipoprotein ratio > or = 3.5 is associated with an increased burden of coronary artery disease on cardiac catheterization. J Cardiometab Syndr 1 (2006) 13-15
53. Rosanoff A., and Seelig M.S. Comparison of mechanism and functional effects of magnesium and statin pharmaceuticals. J Am Coll Nutr 23 (2004) 501S-505S
54. Rasmussen H.S., Aurup P., Goldstein K., McNair P., Mortensen P.B., Larsen O.G., et al. Influence of magnesium substitution therapy on blood lipid composition in patients with ischemic heart disease. A double-blind, placebo controlled study. Arch Intern Med 149 (1989) 1050-1053
55. Corica F., Allegra A., Di Benedetto A., Giacobbe M.S., Romano G., Cucinotta D., et al. Effects of oral magnesium supplementation on plasma lipid concentrations in patients with non-insulin-dependent diabetes mellitus. Magnes Res 7 (1994) 43-47
56. Singh R.B., Rastogi S.S., Mani U.V., Seth J., and Devi L. Does dietary magnesium modulate blood lipids?. Biol Trace Elem Res 30 (1991) 59-64
57. Dinis A.P., Marques R.G., Simões F.C., Diestel C.F., Caetano C.E., Secchin D.J., et al. Plasma lipid levels of rats fed a diet containing pork fat as a source of lipids after splenic surgery. Lipids 44 (2009) 537-543
58. Ferreira F.S., Brito S.V., Ribeiro S.C., Saraiva A.A., Almeida W.O., and Alves R.R. Animal-based folk remedies sold in public markets in Crato and Juazeiro do Norte, Ceará, Brazil. BMC Complement Altern Med 9 (2009) 17